Ajinomoto hones pharma focus by stepping back from infusions and dialysis
This article was originally published in Scrip
The wholly owned pharmaceuticals subsidiary of Japan's diversified Ajinomoto group is spinning off its infusion solutions and dialysis product business into a new joint venture to be majority owned by the Japanese generic drug firm Yoshindo.
You may also be interested in...
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.